SEARCH:   Advanced

Blood, 15 February 2007, Vol. 109, No. 4, pp. 1408-1413. Prepublished online as a Blood First Edition Paper on October 24, 2006; DOI 10.1182/blood-2006-03-011908. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-03-011908v1 109/4/1408    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by de Labarthe, A. Articles by Dombret, H. Search for Related Content PubMed PubMed Citation Articles by de Labarthe, A. Articles by Dombret, H. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 22, 2006 Accepted August 21, 2006 Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia - Results of the GRAAPH-2003 study Adrienne de Labarthe, Philippe Rousselot, Francoise Huguet-Rigal, Eric Delabesse, Francis Witz, Sebastien Maury, Delphine Rea, Jean-Michel Cayuela, Marie-Christine Vekemans, Oumedaly Reman, Agnes Buzyn, Arnaud Pigneux, Martine Escoffre, Yves Chalandon, Elizabeth MacIntyre, Veronique Lheritier, Jean-Paul Vernant, Xavier Thomas, Norbert Ifrah, and Herve Dombret* Department of Hematology, Hopital Saint-Louis, Paris, France Department of Hematology, Hopital Andre Mignot, Versailles, France Department of Hematology, Hopital Purpan, Toulouse, France Department of Hematology, Hopital Necker, Paris, France Department of Hematology, Hopital de Brabois, Nancy, France Department of Hematology, Hopital Henri Mondor, Creteil, France Department of Hematology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium Department of Hematology, Centre Hospitalier Universitaire, Caen, France Department of Hematology, Hopital Haut-Leveque, Pessac, France Department of Hematology, Centre Hospitalier Universitaire, Rennes, France Department of Hematology, Hopital Universitaire, Geneve, Switzerland Department of Hematology, Hopital Edouard Herriot, Lyon, France Department of Hematology, Hopital Pitie-Salpetriere, Paris, France Department of Hematology, Centre Hospitalier Universitaire, Angers, France * Corresponding author; email: herve.dombret{at}sls.ap-hop-paris.fr. Combination of imatinib with chemotherapy has been recently reported as very promising in patients with Ph+ ALL. During 2004 and 2005, 45 patients with newly-diagnosed Ph+ ALL were treated in the GRAAPH-2003 study in which imatinib was started with HAM consolidation in good early responders (cortico- and chemo-sensitive ALL) or earlier during the induction course in combination with dexamethasone and vincristine in poor early responders (cortico- and/or chemo-resistant ALL). Imatinib was then continuously administered until stem cell transplantation (SCT). Overall, complete remission (CR) and BCR-ABL RQ-PCR negativity rates were 96% and 29%, respectively. All the 22 CR patients (100%) with a donor actually received allogeneic SCT in first CR. At 18 months, estimated cumulative incidence of relapse, disease-free and overall survival were 30%, 51%, and 65%, respectively. These three endpoints compared very favorably with results obtained in the pre-imatinib LALA-94 trial. This study confirms the value of the combined approach and encourages prospective trials to define the optimal chemotherapy which has to be combined with imatinib and carefully re-evaluate the place of allogeneic SCT in this new context. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020